Washington—Reducing the number of adverse drug reactions in the United States will take a concerted effort on the part of everyone involved, not just pharmaceutical manufacturers and regulators but physicians, patients, policymakers, and health plan administrators. New direction and leadership at the highest level are needed if drug safety is to be ensured, said participants in a symposium on drug safety held here last month by the Center for Drug Development Science at Georgetown University Medical Center.
Marwick C. Drug Safety Takes Cooperation. JAMA. 1999;282(4):315-316. doi:10.1001/jama.282.4.315-JMN0728-3-1